Taro Pharmaceutical was one of the rare exceptions of a stock that advanced while the S&P 500 descended into a bear market.

Wyost is approved for the treatment of cancer-related bone disease and Jubbonti is approved to treat osteoporosis.

GameSpot may get a commission from retail offers. For the last two decades, Yoko Taro has found success with the Drakengard and Nier franchise(s), but he hasn't had a new game since the Voice of Cards ...

Yoko Taro, the creator of the Nier and Drakenguard games, has been awfully quiet lately. Though he's worked on some smaller projects (writing scenarios for Voice of Cards, and a few mobile games), the ...

AFTER AMERICA, China is the world’s largest developer of new medicines. Its companies ran nearly a third of the planet’s clinical trials last year. That is up from just 5% a decade before (see chart 1 ...

A federal judge officially approved drugmaker Purdue Pharma's $7.4 billion deal to settle thousands of lawsuits over the toll of the opioid epidemic and pay victims, prosecutors in the case told USA ...

Many internet ventures lost money and a large number went bankrupt in the 1990s. But America Online showed rapid growth.

In this week’s edition of InnovationRx, we look at the biotech deal frenzy, Recursion’s incoming CEO, the infant formula botulism outbreak, and more. To get it in your inbox, subscribe here. Merck ...

The global pharmaceutical market is valued at $1.7 trillion, offering lucrative investment prospects. Choosing the right pharmaceutical stocks involves evaluating consistent revenue growth and robust ...

The investment seeks capital appreciation. The fund normally invests at least 80% of assets in companies engaged in the research, development, manufacture, sale, or distribution of pharmaceuticals and ...

Sweden's Sobi to buy US biotech Arthrosi for up to $1.5 billion to boost gout pipeline Drugmaker Swedish Orphan Biovitrum said on Saturday it had agreed to acquire U.S.-based biotechnology company ...

Nov 18 (Reuters) - Global drugmakers are rushing to boost U.S. manufacturing and inventory as the Trump administration weighs a 100% tariff on imported branded and patented drugs. Although enforcement ...